Search

Your search keyword '"García, Héctor"' showing total 50 results
Start Over Author "García, Héctor" Publisher elsevier ltd
50 results on '"García, Héctor"'

1. The NITRATE-OCT study-inorganic nitrate reduces in-stent restenosis in patients with stable coronary artery disease: a double-blind, randomised controlled trial

Author

Rathod, Krishnaraj S., Mathur, Anthony, Shabbir, Asad, Khambata, Rayomand S., Lau, Clement, Beirne, Anne-Marie, Chhetri, Ismita, Ono, Mutsumi, Belgaid, Djouhar R., Massimo, Gianmichele, Ramasamy, Anantharaman, Tufaro, Vincenzo, Jain, Ajay K., Poulter, Neil, Falaschetti, Emanuela, Jones, Daniel A., Garcia-Garcia, Hector M., Bourantas, Christos, Learoyd, Anna, Warren, Helen R., and Ahluwalia, Amrita

Published
2024
Full Text
View/download PDF

2. Mass chemotherapy with niclosamide for the control of Taenia solium: population-based safety profile and treatment effectiveness

Author

Verastegui, Manuela R., Bustos, Javier A., Zimic, Mirko, Gonzales, Isidro, Saavedra, Herbert, Sanchez, Sofia S., Martinez, Manuel, Castillo, Yesenia, Toribio, Luz, Arroyo, Gianfranco, Orrego, Miguel A., Chile, Nancy, Mayta, Holger, Pajuelo, Monica, Santivañez, Saul, Gonzalez-Gustavson, Eloy, Gomez-Puerta, Luis, Gavidia, Cesar M., Vargas-Calla, Ana, Lopez, Maria T., Nash, Theodore E., Handali, Sukwan, Noh, John, Friedland, Jon, Wardle, Melissa T., Allen, Samantha E., Gamboa, Ricardo, Vilchez, Percy, O'Neal, Seth E., Muro, Claudio, Lescano, Andrés G., Moyano, Luz M., Gonzalvez, Guillermo E., González, Armando E., Gilman, Robert H., and García, Héctor H.

Published
2024
Full Text
View/download PDF

6. Association of hepatitis B virus treatment with all-cause and liver-related mortality among individuals with HBV and cirrhosis: a population-based cohort study

Author

Makuza, Jean Damascene, Jeong, Dahn, Wong, Stanley, Binka, Mawuena, Adu, Prince Asumadu, Velásquez García, Héctor Alexander, Morrow, Richard L., Cua, Georgine, Yu, Amanda, Alvarez, Maria, Bartlett, Sofia, Ko, Hin Hin, Yoshida, Eric M., Ramji, Alnoor, Krajden, Mel, and Janjua, Naveed Zafar

Published
2024
Full Text
View/download PDF

10. Safety and performance of the third-generation drug-eluting resorbable coronary magnesium scaffold system in the treatment of subjects with de novo coronary artery lesions: 6-month results of the prospective, multicenter BIOMAG-I first-in-human study

Author

Haude, Michael, Wlodarczak, Adrian, van der Schaaf, René J., Torzewski, Jan, Ferdinande, Bert, Escaned, Javier, Iglesias, Juan F., Bennett, Johan, Toth, Gabor, Joner, Michael, Toelg, Ralph, Wiemer, Marcus, Olivecrona, Göran, Vermeersch, Paul, Garcia-Garcia, Hector M., and Waksman, Ron

Published
2023
Full Text
View/download PDF

31. Safety and performance of the second-generation drug-eluting absorbable metal scaffold in patients with de-novo coronary artery lesions (BIOSOLVE-II): 6 month results of a prospective, multicentre, non-randomised, first-in-man trial

Author

Haude, Michael, Ince, Hüseyin, Abizaid, Alexandre, Toelg, Ralph, Lemos, Pedro Alves, von Birgelen, Clemens, Christiansen, Evald Høj, Wijns, William, Neumann, Franz-Josef, Kaiser, Christoph, Eeckhout, Eric, Lim, Soo Teik, Escaned, Javier, Garcia-Garcia, Hector M, and Waksman, Ron

Published
2016
Full Text
View/download PDF

33. A bioresorbable everolimus-eluting scaffold versus a metallic everolimus-eluting stent for ischaemic heart disease caused by de-novo native coronary artery lesions (ABSORB II): an interim 1-year analysis of clinical and procedural secondary outcomes from a randomised controlled trial

Author

Serruys, Patrick W, Chevalier, Bernard, Dudek, Dariusz, Cequier, Angel, Carrié, Didier, Iniguez, Andres, Dominici, Marcello, van der Schaaf, René J, Haude, Michael, Wasungu, Luc, Veldhof, Susan, Peng, Lei, Staehr, Peter, Grundeken, Maik J, Ishibashi, Yuki, Garcia-Garcia, Hector M, and Onuma, Yoshinobu

Published
2015
Full Text
View/download PDF

40. CONTRIBUTORS

Author

Abahuje, Egide, Abrahim, Orit, Adetifa, Ifedayo M.O., Ajjampur, Sitara S.R., Alexander, Suceena, PhD, Chiara Altare, Alves, Fabiana, Andrianaivoarimanana, Voahangy, Angelakis, Emmanouil, Aronson, Jeffrey K., Atukorala, Inoshi G., Baily, Guy, Baker, Stephen, Barrett, Alan D.T., Basnyat, Buddha, Bastawrous, Andrew, Bates, Imelda, Bausch, Daniel G., Baxter, Cheryl, Beare, Nicholas A.V., Beeching, Nick J., Bekker, Linda-Gail, Berlin, Anita, FRS, Zulfiqar A. Bhutta, Bloom, David E., Blumberg, Lucille, Boelaert, Marleen, Brett-Major, David, Brooker, Simon J., Brouwer, Matthijs C., Brunetti, Enrico, Bull, Susan, Bundy, Donald A.P., Burri, Christian, Bustinduy, Amaya L., Caillet, Céline, Chai, Jong Yil, Chang, Thashi, Chappuis, François, Chibi, Buyisile, Chiodini, Peter L., Chowdhury, Rajiv, Chowdhury, Sudipta Dhar, Clemens, John D., Cooke, Graham S., Cotton, Mark F., Currie, Bart J., Cusack, Tomas-Paul, Dance, David A.B., Davis, Emily H., Day, Nicholas P.J., Deen, Jacqueline, Dondorp, Arjen M., Dünser, Martin W., Eitzen, Edward, Chebib, Hassan El, Enria, Delia, Faust, Christina, Fekadu, Abebaw, Fink, Günther, Fischer, Peter U., Fletcher, Tom, Franco-Paredes, Carlos, French, Neil, Frumkin, Howard, Garcia, Hector H., Gerada, Alessandro, Glass, Roger I., Gordon, Stephen B., Gottstein, Bruno, Goyal, Alpesh, Grey, Jonathan, Gupta, Yashdeep, Haines, Andy, Hampson, Katie, Hanlon, Charlotte, Harrison, Mark, Haswell, Melissa R., Hawkesworth, Sophie, Hay, Roderick J., Heckmann, Jeannine M., Heimesaat, Markus M., Henao-Martínez, Andrés F., Hien, Tran Tinh, Hoerauf, Achim, Irfan, Omar, PhD, Euzebiusz Jamrozik, Jobe, Modou, John, George T., Jones, Nick K., Jones, Malcolm K., Junghanss, Thomas, Kaewkes, Sasithorn, Karim, Quarraisha Abdool, Keiser, Jennifer, Kelly, Paul, Khan, Amira M., King, Charles H., Kishore, Sandeep P., Lang, Trudie, Le, Thuy, Liesenfeld, Oliver, Lockwood, Diana N.J., Mabey, David C.W., Madkour, M. Monir, Manesh, Abi, Masekela, Refiloe, Mäser, Pascal, Mayaud, Philippe, Mbanya, Dora, McCarthy, James S., McCartney, Daniel J., McGready, Rose, McKee, Martin, Mc, Namara, Paul S., Meara, John G., Meintjes, Graeme, Merson, Laura, Mola, Glen, Morassutti, Alessandra L., Morris-Jones, Rachael, Mortimer, Kevin J., Muliyil, Divya Elizabeth, Mumcuoglu, Kosta Y., Munoz, Flor M., Murphy, Adrianna, Mutabingwa, Theonest, Nawa, Yukifumi, Newton, Paul N., Nightingale, Sam, Nokes, D. James, Nosten, François H., O’Hea, Jennifer, Olliaro, Piero, Ong, Jason J., Oommen, Anu Mary, Parashar, Umesh D., Paris, Daniel H., Parker, Michael, Pluschke, Gerd, Preidis, Geoffrey A., Prentice, Andrew M., Quail, Geoffrey, Quinn, Thomas C., Rabie, Helena, Rajashekharaiah, Harsha, Rajerison, Minoarisoa, Ranganathan, Kannan, Raoult, Didier, Rassi, Anis, Jr, Ravi, Vasanthapuram, Reddy, K. Srinath, Rees, Claire, Reynolds, Steven J., Richter, Joachim, Rijken, Marcus J., Riviello, Robert, Robinson, Janet, Salazar, Juan C., Schultz, Marcus J., Schwarz, Dan, Sendagire, Ibrahim, Sharma, Savitri, Shawon, Shajedur Rahman, Singh, Bhagteshwar, Sithithaworn, Paiboon, Siwila, Joyce, Solomon, Tom, Spiegel, Paul, Sridhar, Devi, Sripa, Banchob, Srour, M. Leila, Stojković, Marija, Strader, Christopher, Suárez, Jose A., Sundar, Shyam, Tamarozzi, Francesca, Tandon, Nikhil, Tate, Jacqueline E., Thachil, Jecko, Thomson, Madeleine C., Thwaites, Guy, Thwaites, C. Louise, van Daalen, Kim R., Beek, Diederik van de, van Doorn, H. Rogier, Vega-Lopez, Francisco, von Seidlein, MD, PhD, Lorenz, Wakeham, Katie, Walker, Stephen L., Wallace, Ryan M., Ward, Honorine, Warrell, David A., Weber, Tim Frederik, Weil, Gary J., White, Nicholas J., White, MB Ch, B, Graham B., Wong, Vanessa, Wood, Robin, Wood, Georgina, Wyllie, Sarah, Yacoub, Sophie, Yen, Lam Minh, Young, Paul R., and Zafren, Ken

Published
2024
Full Text
View/download PDF

49. Mass chemotherapy with niclosamide for the control of Taenia solium : population-based safety profile and treatment effectiveness.

Author

Wardle MT, Allen SE, Gamboa R, Vilchez P, O'Neal SE, Muro C, Lescano AG, Moyano LM, Gonzalvez GE, González AE, Gilman RH, and García HH

Abstract

Background: Mass drug administration (MDA) with niclosamide (NSM) can be used to control taeniasis, the cause of neurocysticercosis. NSM is 84.3% effective against taeniasis and is considered safe as it is not absorbed from the intestinal tract. However, information on its safety and effectiveness during MDA is limited. We evaluated the effectiveness of NSM and reported adverse events (AEs) during a cysticercosis elimination program in Tumbes, Peru., Methods: Three rounds of NSM at 4-month intervals were offered to 77,397 eligible residents. We revisited all participants in their homes 72 h after each round to collect information regarding AEs. We also collected post-treatment stool samples to diagnose taeniasis after the first round, followed by a second sample at 30 days from those infected to evaluate NSM's effectiveness., Findings: During implementation, 68,751 individuals were administered at least one dose of NSM (mean age 29 years, SD 20; 52% male), and 65,551 (95.3%) were visited post-treatment. 988 (1.5%) reported experiencing at least one AE. Almost all AEs (99.2%) were of mild intensity, with no severe AEs recorded. Of 211 participants diagnosed with taeniasis, 188 provided a follow-up stool sample 30-days after treatment and 141 were cured (treatment effectiveness 75.0%). Older age and higher coproantigen levels were significantly associated with treatment failure., Interpretation: MDA with NSM is safe in Taenia solium endemic settings. However, the effectiveness following one dose is lower than expected, which suggests additional treatment may be necessary to enhance the infection control efforts., Funding: The Bill and Melinda Gates Foundation., Competing Interests: RG, PV, CM, and LMM were partially supported by the US National Institutes of Health, the Fogarty International Center (TW001140), AGL was supported by Emerge, the Emerging Diseases Epidemiology Research Training of the US National Institutes of Health, the Fogarty International Center (D43 TW007393), and MTW was supported by the National Center for Advancing Translational Sciences of the US National Institutes of Health under award number (TL1TR00237). HG was supported by a Wellcome Trust International Senior Research Fellowship in Public Health and Tropical Medicine. All authors declare no conflicts of interests., (© 2024 The Author(s).)

Published
2024
Full Text
View/download PDF

50. Treatment of HCV with direct-acting antivirals on reducing mortality related to extrahepatic manifestations: a large population-based study in British Columbia, Canada.

Author

Jeong D, Wong S, Karim ME, Manges AR, Makuza JD, Bartlett SR, Velásquez García HA, Luster D, Adu PA, Binka M, Yu A, Krajden M, and Janjua NZ

Abstract

Background: HCV infection is associated with mortality due to extrahepatic manifestations (EHM). Sustained virologic response (SVR) following direct-acting antiviral (DAA) therapy has been linked to decreased all-cause and liver-related mortality. However, evidence regarding the impact of DAA on EHM-related deaths is lacking. This study aimed to assess the impact of DAA and SVR on EHM-related mortality., Methods: The British Columbia Hepatitis Testers Cohort comprises ∼1.7 million people tested for HCV between 1990 and 2015 and is linked with administrative health data. Among individuals diagnosed with HCV by 12/31/2020, those who received at least one DAA treatment were matched to those who never received treatment by the year of their first HCV RNA positive date. We compared three groups: treated & SVR, treated & no-SVR, and untreated; and generated EHM mortality rates and incidence curves. To account for differences in baseline characteristics, we used inverse probability of treatment weights (IPTW). IPTW-weighted multivariable cause-specific Cox regression models were adjusted for competing risk and confounders., Findings: Study population included 12,815 treated (12,287 SVR, 528 no-SVR) and 12,815 untreated individuals (median follow-up 3.4 years, IQR 2.9). The untreated group had the highest EHM mortality rate (30.9 per 1000 person-years [PY], 95% CI 29.2-32.8), followed by the treated & no-SVR group (21.2 per 1000 PY, 95% CI 14.9-30.1), while the treated & SVR group had the lowest EHM mortality rate (7.9 per 1000 PY, 95% CI 7.1-8.7). In the multivariable model, EHM mortality in the treated & SVR group was significantly decreased (adjusted cause-specific hazard ratio [acsHR] 0.20, 95% CI 0.18-0.23). The treated & SVR group had significant reductions in mortality related to each of the EHMs (78-84%)., Interpretation: Treatment of HCV with DAA was associated with significant reductions in EHM-related mortality. These findings emphasize the critical importance of timely diagnosis and treatment of HCV to prevent deaths associated with EHM, and have important implications for clinical practice and public health., Funding: This work was supported by the BC Centre for Disease Control and the Canadian Institutes of Health Research (CIHR) [Grant # NHC-348216, PJT-156066, and PHE-337680]. DJ has received Doctoral Research Award (#201910DF1-435705-64343) from the Canadian Institutes of Health Research (CIHR) and Doctoral fellowship from the Canadian Network on Hepatitis C (CanHepC). CanHepC is funded by a joint initiative of the Canadian Institutes of Health Research (CIHR) (NHC-142832) and the Public Health Agency of Canada (PHAC)., Competing Interests: MK has received grant/research support from Roche, Merck, Siemens, Boeringer Ingelheim and Hologic. SRB has consulted for Cepheid, Gilead, and Abbvie, but no personal payments accepted, and has received investigator-initiated grants from Gilead and Abbvie through her institution. NZJ participated in advisory boards and has spoken for AbbVie and Gilead, not related to current work. DJ, SW, MEK, ARM, JDM, HAVG, DL, PA, MB and AY have no conflicts of interest to declare., (© 2023 The Author(s).)

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results